MedTrace Logo

Effect of Arotinolol Hydrochloride on Cardiovascular Events in Hypertensive Haemodialysis Patients

NCT01351636 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2019-04-17

No results posted yet for this study

Summary

The purpose of this study is to ascertain whether Arotinolol Hydrochloride reduces mortality and cardiovascular events in chronic kidney disease stage 5 patients with hypertension.

Conditions

Interventions

DRUG

Arotinolol Hydrochloride

Antihypertensive medications plus arotinolol hydrochloride, dosage of arotinolol hydrochloride from 2.5mg bid, 2 days later increased to 5mg bid or 10mg bid, for 18 months

DRUG

Non arotinolol group

Antihypertensive medications without arotinolol for 18 months

Sponsors & Collaborators

  • Sumitomo Pharma (Suzhou) Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Nan Chen, PhD, MD · Shanghai Jiaotong University Medical School Affiliated Ruijin Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-04-30
Primary Completion
2018-10-10
Completion
2018-10-10

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01351636 on ClinicalTrials.gov